Upul Wickramarachchi

Upul Wickramarachchi

Auto-generated profile, based on publicly available information

Upul Wickramarachchi

Department of Cardiology 578 Elvitigala Mawatha, Narahenpita, Colombo 5, 00500

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in Current Cardiology Reviews
Verified
Journal Article
Open access
PDF file
TGTharusha Gunawardena
Tharusha Gunawardena
IMIoannis Merinopoulos
Ioannis Merinopoulos
UWUpul Wickramarachchi
Upul Wickramarachchi
VVVassilios S. Vassiliou
Vassilios S. Vassiliou
SESimon Charles Eccleshall
Simon Charles Eccleshall
The fervency for advancement and evolution in percutaneous coronary intervention has revolutionised the treatment of coronary artery disease. Historically, the focus of the interventional cardiologist was directed at the restoration of luminal patency of the major epicardial coronary arteries, yet whilst this approach is evolving with much greater utilisation of physiological assessment, it often neglects consideration of the role of the coronary microcirculation, which has been shown to clearly influence prognosis. In this review, we explore the narrative of the coronary circulation as more than just a simple conduit for blood but an organ with functional significance. We review organisation and physiology of the coronary circulation, as well as the current methods and techniques used to examine it. We discuss the studies exploring coronary artery endothelial function, appreciating that coronary artery disease occurs on a spectrum of disorder and that percutaneous coronary intervention has a latent effect on the coronary circulation with long-term consequences. It is concluded that greater recognition of the coronary artery endothelium and mechanisms of the coronary circulation should further guide revascularisation strategies.

30 June 2025 in Postgraduate Medical Journal
Verified
Journal Article
Closed access
DLDilusha Lamabadusuriya
Dilusha Lamabadusuriya
PJPiyumika Jayawardene
Piyumika Jayawardene
FCF. Aaysha Cader
F. Aaysha Cader
UWUpul Wickramarachchi
Upul Wickramarachchi
Objective: To review the role of high-sensitivity C-reactive protein (hsCRP) as a biomarker of inflammation in coronary atherosclerotic disease and its potential clinical applications. Methods: A narrative review of key clinical trials, meta-analyses, and guideline recommendations was performed to evaluate the association between hsCRP levels, cardiovascular risk, and therapeutic interventions. Results: Elevated hsCRP levels are associated with increased risk of coronary events, both in primary and secondary prevention settings. Statins, independent of their lipid-lowering effects, significantly reduce hsCRP levels and associated cardiovascular events. Anti-inflammatory agents such as canakinumab and colchicine also demonstrate benefit in reducing major adverse cardiovascular events, while newer agents like bempedoic acid show promising hsCRP-lowering effects. Current guidelines recommend selective hsCRP use for risk stratification, particularly in intermediate-risk patients. Conclusion: hsCRP is a valuable biomarker reflecting residual inflammatory risk in coronary atherosclerosis. Incorporating hsCRP into routine clinical practice may enhance cardiovascular risk stratification and guide therapeutic decisions. Categories: Cardiology, Internal medicine

4 June 2021 in Heart
Verified
Conference Paper
Open access
PDF file
IMIoannis Merinopoulos
Ioannis Merinopoulos
TGTharusha Gunawardena
Tharusha Gunawardena
NCNatasha Corballis
Natasha Corballis
UWUpul Wickramarachchi
Upul Wickramarachchi
CMCiint Maart
Ciint Maart
SESimon Charles Eccleshall
Simon Charles Eccleshall
Introduction In the setting of primary percutaneous coronary intervention (PPCI), it has been shown that stenting compared to balloon angioplasty (BA) reduces the need for repeat revascularisation but not overall mortality. A recent, small randomised trial showed that drug coated balloon (DCB) angioplasty for PPCI was non-inferior to drug eluting stent (DES) in terms of fractional flow reserve at 9 months. Our aim was to investigate the safety of DCB angioplasty in a STEMI population in terms of all-cause mortality. Methods We identified all patients treated for STEMI in our institution from January 2016 until November 2019. We excluded patients who died in hospital and patients with cardiac arrest, cardiogenic shock or requiring intubation; given that their mortality is more likely to be determined by the severity of their clinical presentation rather than the PCI strategy. The primary endpoint was all-cause mortality. Survival data were obtained through the UK Health and Social Care Information Service. Clinical and angiographic data were collected from our prospectively collated database and supplemented from electronic records where required. All angiograms were reviewed by an experienced operator to confirm treatment strategy, bifurcation lesions, coronary artery dissection and TIMI flow pre- and post-intervention. Results A total of 1190 patients were identified; 470 treated with DCB and 720 with DES. The average age for the DCB group was 65.5 ± 12.5 years old (73.6% male); while for the DES group it was 65.5 ± 11.6 years old (74.7% males). The average follow up was 882 ± 439 days and 978 ± 426 days for the DCB and DES group respectively. There were a few differences between the groups (table 1). There were no differences in all other clinical and angiographic characteristics. The all-cause mortality was 33/470 (7%) for the DCB group and 48/720 (6.7%) for the DES group. Kaplan Meier estimator plot for all-cause mortality (figure 1) did not show a significant difference between DCB and DES (p=0.54). On multivariable Cox regression analysis (table 2), age, prior stroke, coronary artery bypass graft, heart failure, chronic obstructive pulmonary disease (COPD) and diabetes were significant poor predictors of mortality. Conclusion Our real-world data from a large, contemporary cohort of STEMI patients demonstrate that DCB only angioplasty is safe compared to DES and may be considered as a treatment option. Conflict of Interest none